132 related articles for article (PubMed ID: 15269145)
1. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
[TBL] [Abstract][Full Text] [Related]
4. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
[TBL] [Abstract][Full Text] [Related]
7. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of infusional valspodar.
Ma MK; McLeod HL; Westervelt P; Fracasso PM
J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566
[TBL] [Abstract][Full Text] [Related]
9. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
Smith NF; Mani S; Schuetz EG; Yasuda K; Sissung TM; Bates SE; Figg WD; Sparreboom A
Ann Pharmacother; 2010 Nov; 44(11):1709-17. PubMed ID: 20959500
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL
Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923
[TBL] [Abstract][Full Text] [Related]
12. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
14. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD
J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
[TBL] [Abstract][Full Text] [Related]
18. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
